CellAED® Press Release - CorMed-DX

CellAED® Press Release

World-first personal defibrillator, CellAED® available in the UK with CorMed-DX Ltd.
Unique, innovative technology to save lives from Sudden Cardiac Arrest.

CorMed-DX Ltd have partnered with Rapid Response Revival® as an authorised re-seller of CellAED®, the world-first personal defibrillator, created to make AEDs (automated external defibrillators) affordable and easy to use for people with no medical training. Weighing just 300grams and the size of a bar of chocolate, CellAED® can be carried with you or stored very easily.

Sudden cardiac arrest is the world’s biggest cause of premature death, killing between seven and nine million people every year[i].  This is similar to the lives lost from all cancers combined.[ii] 

More than 80 per cent of sudden cardiac arrests occur in the home.[iii]  Before now, AEDs have been too expensive to be a realistic option for the households of people at risk of sudden cardiac arrest, and too complicated to use.

Rapid Response Revival® has solved these problems.  By designing a miniaturised AED that is easy to use, the Sydney-based start-up was also able to reduce the cost to consumers of owning this life-saving technology.

“CorMed-DX are delighted to be working with Rapid Response Revival®, out of hospital sudden cardiac arrests (OHSCA) are a time-sensitive, life threatening emergency that occur too often in the UK. Until now, public access AEDs have been too complicated for a bystander to use confidently, and haven’t been accessible enough. CellAED®is a game changer and resets the clock when “time is everything”; we are 100% certain that this product will save lives, the device is so simple to use, anyone can do it, even a child. We can’t wait to show off this life saving device in the UK.”Craig Hall, MD and Founder of CorMed-DX.

The unique CellAED® Snap Peel Stick™ design allows the AED to be applied in seconds, buying time to save lives from sudden cardiac arrest.

These achievements will improve availability of defibrillators where it’s needed most – in our homes, businesses and communities.

Rapid defibrillation is the only effective treatment for sudden cardiac arrest.[iv]  An AED applied within minutes of a sudden cardiac arrest buys the patient time until emergency services arrive.[v] 

Someone experiencing a sudden cardiac arrest requires rapid defibrillation.  For every minute without defibrillation and CPR, the chances of being revived following a cardiac arrest drops 10 per cent.[vi]

Sudden cardiac arrest has a survival rate of less than one percent.[vii]  This is because it kills so quickly, and because most witnesses to a sudden cardiac arrest don’t have the skills or access to an AED to help save a life,” said Rapid Response Revival® Founder and CEO, Donovan Casey. 

“We created our easy-to-use CellAED® to make our AEDs more affordable, smaller, portable and more accessible so more people have access to this life-saving technology in those critical first few minutes following an out-of-hospital cardiac arrest. 

“It is gratifying to know that smart, innovative Australian technology will soon be saving lives around the world.”

CellAED® is ground-breaking medical technology that emergency first responders, electro-cardiologists, first aid trainers and others dedicated to saving lives from sudden cardiac arrest have been waiting for.

Visit the CorMed-DX website and social media pages for more information:
Website: https://cormed-dx.com
LinkedIn: https://www.linkedin.com/company/cormed-dx/
Facebook: https://www.facebook.com/profile.php?id=100090261890853
Twitter: https://twitter.com/cormeddx/

Get in touch with the CorMed-DX team to discuss your requirements:
Phone: 08003317999
General Enquiries: hello@cormed-dx.com
Product Information: info@cormed-dx.com
Marketing: a.bowe@cormed-dx.com
MD / Founder; Craig Hall is available for interviews.
Please contact info@cormed-dx.com for further details.

request more information

About Rapid Response Revival®
Rapid Response Revival® is a privately-owned Sydney, Australia-based start-up Company, established in 2017.  Its mission is tackling the unacceptably low survival rate of out-of-hospital cardiac arrest.

The Rapid Response Revival® marquee product is CellAED®, designed to make AEDs easier to use, easier to carry, and more affordable.  CellAED® represents the first real improvements on AED technology in more than 30 years and is the world-first personal AED. 

About CellAED®
CellAED® is a world-first personal defibrillator using game-changing technology developed by pioneering Australian med-tech start-up, Rapid Response Revival®.

CellAED® has medical device regulatory clearance for use in more than 70 countries worldwide, including the member states of the European Economic Union, the UK, Australia and New Zealand.  It is the proprietary technology of Rapid Response Revival®.

CorMed-DX Ltd is a licensed CellAED® distributor in the UK.

About CorMed-DX

CorMed-DX Ltd is a privately owned business established by Craig Hall in 2022 after 25 years of experience in providing NHS, Emergency Services, and Specialist Sectors with Technology and Services. With a Global network and a proven track record, we have the knowledge and connections to offer leading edge solutions and products to meet our customer’s needs. Based in Sheffield, South Yorkshire, we are specialists in medical technology, sales and marketing, product development, tender/bid management, and the large roll out of major equipment, software and training projects.

References:
[i] World Health Organisation (WHO) – 2019 figures on deaths attributed to cardiovascular diseases (CVD) culminating in sudden cardiac arrest. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

[ii] World Health Organisation (WHO) – 2020 international figures on deaths attributed to cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

[iii] R M Norris, on behalf of the UK Heart Attack Study (UKHAS) Collaborative Group. Circumstances of out of hospital cardiac arrest in patients with ischaemic heart disease. Heart. 2005 December, 91(12): 1537-1540.

[iv] Kenneth G Spearpoint, C.Paula McLean, David A. Zideman. Early defibrillation and the chain of survival in ‘in-hospital’ adult cardiac arrest; minutes count. Resuscitation. 2000, Volume 44, Issue 3: pp 165-169.

[v] Roger A. Winkle. The effectiveness and cost effectiveness of public-access defibrillation. Clinical Cardiology. 2010 July, Volume 33, Issue 7: pp 396-399.

[vi] Pier D. Lambaise. Reinforcing the links in the chain of survival. Journal of the American College of Cardiology. 2017, Volume 70, No. 9.

[vii] Mehra R. Global public health problem of sudden cardiac death. Journal of Electrocardiology. 2007 Nov-Dec, Volume 40: pp 118-122.

Scroll to Top